David Craig is a highly experienced pharmaceutical executive with a distinguished career spanning over 30 years in the industry. He is currently the CEO of Sarcomatrix Therapeutics, a pre-clinical biotechnology company focused on developing innovative treatments for muscle wasting diseases, starting with muscular dystrophy. He has held several senior leadership positions in various pharmaceutical companies including Amgen, Gilead, and Alexion. He has extensive experience in drug development and commercialization and has led successful global product launches for multiple blockbuster drugs. David is an advisor and consultant to several pharmaceutical companies, where he provides strategic guidance on clinical development and commercialization. His passion for advancing healthcare through innovative solutions and his commitment to improving patient outcomes make him a respected leader in the field.